NF-YA promotes invasion and angiogenesis by upregulating EZH2-STAT3 signaling in human melanoma cells

Xu,Zihan; Sun,Yaowen; Guo,Yadong; Qin,Gaoping; Mu,Shengzhi; Fan,Ronghui; Wang,Benfeng; Gao,Wenjie; Wu,Hangli; Wang,Guodong; Zhang,Zhenxin

doi:10.3892/or.2016.4761

NF-YA promotes invasion and angiogenesis by upregulating EZH2-STAT3 signaling in human melanoma cells

Authors:
- Zihan Xu
- Yaowen Sun
- Yadong Guo
- Gaoping Qin
- Shengzhi Mu
- Ronghui Fan
- Benfeng Wang
- Wenjie Gao
- Hangli Wu
- Guodong Wang
- Zhenxin Zhang
View Affiliations

Affiliations: Department of Burns and Plastic Surgery, Provincial People's Hospital, Xi'an, Shaanxi 710068, P.R. China
Published online on: April 20, 2016 https://doi.org/10.3892/or.2016.4761
Pages: 3630-3638

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The process of angiogenesis is essential for tumor development and metastasis. Vascular endothelial growth factor (VEGF), which is overexpressed in most human cancers, has been demonstrated to be a major modulator of angiogenesis. Thus, inhibition of VEGF signaling has the potential for tumor anti-angiogenic therapy. Signal transducer and activator of transcription-3 (STAT3) is a key regulator for angiogenesis by directly binding to the VEGF promoter to upregulate its transcription. Several factors can enhance STAT3 activity to affect angiogenesis. Here, we found that overexpression of nuclear transcription factor-Y alpha (NF-YA) gene could promote cell invasion and angiogenesis accompanying the increase of STAT3 signaling in human melanoma cells. Moreover, the expression and secretion of VEGF was also found to be upregulated by the overexpression of NF-YA gene in melanoma cells. The STAT3 inhibitor was able to attenuate the upregulation of VEGF induced by NF-YA overexpression. Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of the Polycomb repressive complex 2, enhances STAT3 activity by mediating its lysine methylation. We also showed that NF-YA upregulated the expression of EZH2 and NF-YA‑induced angiogenesis could be inhibited by EZH2 knockdown. Taken together, these findings indicate that overexpression of NF-YA contributes to tumor angiogenesis through EZH2-STAT3 signaling in human melanoma cells, highlighting NF-YA as a potential therapeutic target in human melanoma.

View Figures

View References

1	Tas F: Metastatic behavior in melanoma: Timing, pattern, survival, and influencing factors. J Oncol. 2012:6476842012. View Article : Google Scholar : PubMed/NCBI
2	Geller AC, Clapp RW, Sober AJ, Gonsalves L, Mueller L, Christiansen CL, Shaikh W and Miller DR: Melanoma epidemic: An analysis of six decades of data from the Connecticut Tumor Registry. J Clin Oncol. 31:417–4178. 2013. View Article : Google Scholar
3	Mehlen P and Puisieux A: Metastasis: A question of life or death. Nat Rev Cancer. 6:449–458. 2006. View Article : Google Scholar : PubMed/NCBI
4	Lamalice L, Le Boeuf F and Huot J: Endothelial cell migration during angiogenesis. Circ Res. 100:782–794. 2007. View Article : Google Scholar : PubMed/NCBI
5	Schaafhausen MK, Yang WJ, Centanin L, Wittbrodt J, Bosserhoff A, Fischer A, Schartl M and Meierjohann S: Tumor angiogenesis is caused by single melanoma cells in a manner dependent on reactive oxygen species and NF-κB. J Cell Sci. 126:3862–3872. 2013. View Article : Google Scholar : PubMed/NCBI
6	Ellis LM and Hicklin DJ: VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nat Rev Cancer. 8:579–591. 2008. View Article : Google Scholar : PubMed/NCBI
7	Welti J, Loges S, Dimmeler S and Carmeliet P: Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest. 123:3190–3200. 2013. View Article : Google Scholar : PubMed/NCBI
8	Jia X, Hong Q, Lei L, Li D, Li J, Mo M, Wang Y, Shao Z, Shen Z, Cheng J, et al: Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer. Oncotarget. 6:8648–8662. 2015. View Article : Google Scholar : PubMed/NCBI
9	Yeh JJ and Kim WY: Targeting tumor hypoxia with hypoxia-activated prodrugs. J Clin Oncol. 33:1505–1508. 2015. View Article : Google Scholar : PubMed/NCBI
10	Cao D, Zhou H, Zhao J, Jin L, Yu W, Yan H, Hu Y and Guo T: PGC-1α integrates glucose metabolism and angiogenesis in multiple myeloma cells by regulating VEGF and GLUT-4. Oncol Rep. 31:1205–1210. 2014.PubMed/NCBI
11	Zhang C, Li Y, Cornelia R, Swisher S and Kim H: Regulation of VEGF expression by HIF-1α in the femoral head cartilage following ischemia osteonecrosis. Sci Rep. 2:6502012. View Article : Google Scholar
12	Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN and Hsieh CY: Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene. 22:1517–1527. 2003. View Article : Google Scholar : PubMed/NCBI
13	Kimura H, Weisz A, Kurashima Y, Hashimoto K, Ogura T, D'Acquisto F, Addeo R, Makuuchi M and Esumi H: Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: Control of hypoxia-inducible factor-1 activity by nitric oxide. Blood. 95:189–197. 2000.
14	Levy DE and Darnell JE Jr: Stats: Transcriptional control and biological impact. Nat Rev Mol Cell Biol. 3:651–662. 2002. View Article : Google Scholar : PubMed/NCBI
15	Zhuang S: Regulation of STAT signaling by acetylation. Cell Signal. 25:1924–1931. 2013. View Article : Google Scholar : PubMed/NCBI
16	Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, et al: Constitutive activation of Stat3 in human prostate tumors and cell lines: Direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 62:6659–6666. 2002.PubMed/NCBI
17	Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, et al: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 21:2000–2008. 2002. View Article : Google Scholar : PubMed/NCBI
18	Rao RA, Dhele N, Cheemadan S, Ketkar A, Jayandharan GR, Palakodeti D and Rampalli S: Ezh2 mediated H3K27me3 activity facilitates somatic transition during human pluripotent reprogramming. Sci Rep. 5:82292015. View Article : Google Scholar : PubMed/NCBI
19	Caganova M, Carrisi C, Varano G, Mainoldi F, Zanardi F, Germain PL, George L, Alberghini F, Ferrarini L, Talukder AK, et al: Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. J Clin Invest. 123:5009–5022. 2013. View Article : Google Scholar : PubMed/NCBI
20	Lee JM, Lee JS, Kim H, Kim K, Park H, Kim JY, Lee SH, Kim IS, Kim J, Lee M, et al: EZH2 generates a methyl degron that is recognized by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex. Mol Cell. 48:572–586. 2012. View Article : Google Scholar : PubMed/NCBI
21	Gunawan M, Venkatesan N, Loh JT, Wong JF, Berger H, Neo WH, Li LY, La Win MK, Yau YH, Guo T, et al: The methyltransferase Ezh2 controls cell adhesion and migration through direct methylation of the extranuclear regulatory protein talin. Nat Immunol. 16:505–516. 2015. View Article : Google Scholar : PubMed/NCBI
22	Tong Q, He S, Xie F, Mochizuki K, Liu Y, Mochizuki I, Meng L, Sun H, Zhang Y, Guo Y, et al: Ezh2 regulates transcriptional and posttranslational expression of T-bet and promotes Th1 cell responses mediating aplastic anemia in mice. J Immunol. 192:5012–5022. 2014. View Article : Google Scholar : PubMed/NCBI
23	Kim E, Kim M, Woo DH, Shin Y, Shin J, Chang N, Oh YT, Kim H, Rheey J, Nakano I, et al: Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell. 23:839–852. 2013. View Article : Google Scholar : PubMed/NCBI
24	Domashenko AD, Wiener S and Emerson SG: NF-Ya protein delivery as a tool for hematopoietic progenitor cell expansion. Methods Mol Biol. 916:303–316. 2012. View Article : Google Scholar : PubMed/NCBI
25	Lin YC, Chen YN, Lin KF, Wang FF, Chou TY and Chen MY: Association of p21 with NF-YA suppresses the expression of Polo-like kinase 1 and prevents mitotic death in response to DNA damage. Cell Death Dis. 5:e9872014. View Article : Google Scholar : PubMed/NCBI
26	Domashenko AD, Danet-Desnoyers G, Aron A, Carroll MP and Emerson SG: TAT-mediated transduction of NF-Ya peptide induces the ex vivo proliferation and engraftment potential of human hematopoietic progenitor cells. Blood. 116:2676–2683. 2010. View Article : Google Scholar : PubMed/NCBI
27	Jin S, Fan F, Fan W, Zhao H, Tong T, Blanck P, Alomo I, Rajasekaran B and Zhan Q: Transcription factors Oct-1 and NF-YA regulate the p53-independent induction of the GADD45 following DNA damage. Oncogene. 20:2683–2690. 2001. View Article : Google Scholar : PubMed/NCBI
28	Matuoka K and Chen KY: Possible role of subunit A of nuclear factor Y (NF-YA) in normal human diploid fibroblasts during senescence. Biogerontology. 1:261–271. 2000. View Article : Google Scholar
29	Orgaz JL, Pandya P, Dalmeida R, Karagiannis P, Sanchez-Laorden B, Viros A, Albrengues J, Nestle FO, Ridley AJ, Gaggioli C, et al: Diverse matrix metalloproteinase functions regulate cancer amoeboid migration. Nat Commun. 5:42552014. View Article : Google Scholar : PubMed/NCBI
30	Eustace AJ, Crown J, Clynes M and O'Donovan N: Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. J Transl Med. 6:532008. View Article : Google Scholar : PubMed/NCBI
31	Herraiz C, Calvo F, Pandya P, Cantelli G, Rodriguez-Hernandez I, Orgaz JL, Kang N, Chu T, Sahai E and Sanz-Moreno V: Reactivation of p53 by a cytoskeletal sensor to control the balance between DNA damage and tumor dissemination. J Natl Cancer Inst. 108:pii: djv289. 2015.PubMed/NCBI
32	Judd LM, Menheniott TR, Ling H, Jackson CB, Howlett M, Kalantzis A, Priebe W and Giraud AS: Inhibition of the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and in vivo. PLoS One. 9:e959932014. View Article : Google Scholar : PubMed/NCBI
33	Zhou X, Ren Y, Liu A, Han L, Zhang K, Li S, Li P, Li P, Kang C, Wang X, et al: STAT3 inhibitor WP1066 attenuates miRNA-21 to suppress human oral squamous cell carcinoma growth in vitro and in vivo. Oncol Rep. 31:2173–2180. 2014.PubMed/NCBI
34	Garipov A, Li H, Bitler BG, Thapa RJ, Balachandran S and Zhang R: NF-YA underlies EZH2 upregulation and is essential for proliferation of human epithelial ovarian cancer cells. Mol Cancer Res. 11:360–369. 2013. View Article : Google Scholar : PubMed/NCBI
35	Nishida N, Yano H, Nishida T, Kamura T and Kojiro M: Angiogenesis in cancer. Vasc Health Risk Manag. 2:213–219. 2006. View Article : Google Scholar
36	Xue Y, Lim S, Yang Y, Wang Z, Jensen LD, Hedlund EM, Andersson P, Sasahara M, Larsson O, Galter D, et al: PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nat Med. 18:100–110. 2011. View Article : Google Scholar : PubMed/NCBI
37	Mahabeleshwar GH and Byzova TV: Angiogenesis in melanoma. Semin Oncol. 34:555–565. 2007. View Article : Google Scholar : PubMed/NCBI
38	Shibuya M: Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A crucial target for anti- and proangiogenic therapies. Genes Cancer. 2:1097–1105. 2011. View Article : Google Scholar
39	Detmar M: Tumor angiogenesis. J Investig Dermatol Symp Proc. 5:20–23. 2000. View Article : Google Scholar